RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1282
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained its 'Outperform' rating on Regeneron Pharmaceuticals and raised the price target from $1250 to $1282, indicating confidence in the company's future performance.
September 09, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its positive outlook on Regeneron Pharmaceuticals by maintaining an 'Outperform' rating and increasing the price target from $1250 to $1282. This suggests confidence in the company's growth prospects.
The increase in price target from $1250 to $1282 by RBC Capital, along with maintaining an 'Outperform' rating, indicates a positive outlook for Regeneron Pharmaceuticals. This is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100